过去一年中添加的文章，按日期排序
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
14 天前 - … Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor 426 agonists
in patients with … • Use of any GLP-1 receptor agonist within 30 days prior to screening 552 …
in patients with … • Use of any GLP-1 receptor agonist within 30 days prior to screening 552 …
912-P: Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
D EDMONSTON, H MULDER, E LYDON… - Diabetes, 2024 - Am Diabetes Assoc
25 天前 - … weighting, we compared kidney and cardiovascular outcomes for initiators of …
kidney outcome was a composite of 40% eGFR decline, incident ESKD, or all-cause mortality …
kidney outcome was a composite of 40% eGFR decline, incident ESKD, or all-cause mortality …
[HTML][HTML] … significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease
P Care, A Bryant, E Fordham, A Hogg, C Steele… - medicalupdateonline.com
42 天前 - … kidney protection and reduced cardiovascular risks, many individuals continue to
experience declining kidney function and adverse outcomes. This … GLP-1 receptor agonists. …
experience declining kidney function and adverse outcomes. This … GLP-1 receptor agonists. …
[HTML][HTML] … risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study …
V Perkovic - pharmiweb.com
46 天前 - … kidney protection and reduced cardiovascular risks, many individuals continue to
experience declining kidney function and adverse outcomes. This … GLP-1 receptor agonists. …
experience declining kidney function and adverse outcomes. This … GLP-1 receptor agonists. …
SGLT-2 Inhibitors in Patients with Chronic Kidney Diseases-A commentary on" Empagliflozin in Patients with Chronic Kidney Disease"
TTM Huang, TS Lai - Formosan Journal of Endocrinology and …, 2024 - airitilibrary.com
62 天前 - … with significant morbidity and mortality. The existing … to end-stage kidney disease
(ESKD) and associated cardiovascular … -1 (GLP-1) agonists and nonsteroidal mineralocorticoid …
(ESKD) and associated cardiovascular … -1 (GLP-1) agonists and nonsteroidal mineralocorticoid …
Pharmacologic Approaches to Glycemic Treatment
BEAB BUSTER - europepmc.org
64 天前 - … CV death, all-cause mortality, MI, HHF, and renal outcomes in individuals with T2D
with established/high risk of CVD; # For GLP-1 … for GLP-1 or dual GIP/GLP-1 receptor agonist …
with established/high risk of CVD; # For GLP-1 … for GLP-1 or dual GIP/GLP-1 receptor agonist …
“Heart” Outcome in Organ Transplant Recipients With Diabetes: Is GLP-1-RA the Leader of the Pack?
WH Lim, G Wong - Transplantation, 2024 - journals.lww.com
78 天前 - … nonfatal CVD events, ischemic stroke, and all-cause death; 101 events/1000
patient-years in GLP-1 receptor agonist users … Cardiovascular, mortality, and kidney outcomes with …
patient-years in GLP-1 receptor agonist users … Cardiovascular, mortality, and kidney outcomes with …
Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease: Results from the EMPRISE study
PT Htoo, E Patorno, H Tesfaye… - Diabetologie und …, 2024 - thieme-connect.com
82 天前 - … risk of cardiovascular disease, heart failure, and mortality. We … Here, we aimed to
assess the cardiovascular … Primary outcomes were hospitalization for heart failure (HHF), a …
assess the cardiovascular … Primary outcomes were hospitalization for heart failure (HHF), a …
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes. Data from the Swedish Heart Failure and Swedish …
M Wallner, ME Biber, D Stolfo, G Sinagra… - … -Cardiovascular …, 2024 - academic.oup.com
82 天前 - … were to investigate GLP-1 RA use, patient characteristics … with mortality/morbidity
in an unselected cohort of HF patients … Cardiovascular, mortality, and kidney outcomes with …
in an unselected cohort of HF patients … Cardiovascular, mortality, and kidney outcomes with …
… PERCUTANEOUS CORONARY INTERVENTION STRATIFIED BY TREATMENT WITH OR WITHOUT GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONISTS
98 天前 - … Glucagon like peptide -1 receptor agonists (GLP-1 RA) are a … major adverse
cardiovascular events (MACE) in patients with … Primary outcome was MACE (ie, all-cause …
cardiovascular events (MACE) in patients with … Primary outcome was MACE (ie, all-cause …